Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty

• Published in: Osteoporosis international 2007-07, Vol.18 (7), p.1009-1015
• Main Authors: YAMASAKI, S, MASUHARA, K, YAMAGUCHI, K, NAKAI, T, FUJI, T, SEINO, Y
• Format: Article
• Language: English
• Subjects: Absorptiometry, Photon; Administration, Oral; Aged; Arthroplasty, Replacement, Hip - methods; Biological and medical sciences; Bisphosphonates; Bone density; Bone Density - drug effects; Bone Density Conservation Agents - administration & dosage; Bone loss; Bone mineral density; Bone resorption; Bone Resorption - drug therapy; Bones, joints and connective tissue. Antiinflammatory agents; Clinical outcomes; Drug therapy; Dual energy X-ray absorptiometry; Dyspepsia; Etidronic acid; Etidronic Acid - administration & dosage; Etidronic Acid - analogs & derivatives; Female; Fundamental and applied biological sciences. Psychology; Hip; Hip joint; Hip Joint - diagnostic imaging; Hip Joint - surgery; Humans; Investigative techniques, diagnostic techniques (general aspects); Joint replacement surgery; Joint surgery; Male; Medical sciences; Middle Aged; Osteoarticular system. Muscles; Osteoporosis; Osteoporosis - drug therapy; Osteoporosis - surgery; Patients; Pharmacology. Drug treatments; Postoperative Complications - drug therapy; Radiodiagnosis. Nmr imagery. Nmr spectrometry; Risedronic Acid; Skeleton and joints; Total hip arthroplasty; Treatment Outcome; Vertebrates: osteoarticular system, musculoskeletal system
• ISSN: 0937-941X; 1433-2965
• DOI: 10.1007/s00198-007-0339-7

Forty-three patients who had undergone cementless THA were randomly assigned to receive no osteoactive drug or oral risedronate for 6 months. Postoperative decrease of BMD in the risedronate group was significantly lower than that seen in the control group in zones 1, 2, 3, 6, and 7. Proximal bone resorption around the femoral stem often has been observed after total hip arthroplasty (THA), could lead to late stem loosening. We previously reported the efficacy of etidronate on periprosthetic bone resorption after cementless THA. Recently risedronate is suggested to be effective for the prevention and treatment of for osteoporosis. The purpose of the present study was to evaluate the effects of risedronate on periprosthetic bone loss after cementless THA. Forty-three patients who had undergone cementless THA were randomly assigned to receive no osteoactive drug (21 patients) or oral risedronate 2.5 mg/day (22 patients) for 6 months. Three patients were eliminated from the risedronate group because of dyspepsia. Periprosthetic bone mineral density (BMD) in seven regions of interest based on the zones of Gruen et al. was measured with dual energy X-ray absorptiometry at 3 weeks and 6 months postoperatively. At 6 months after surgery, postoperative decrease of BMD in the risedronate group was significantly lower than that seen in the control group in zones 1, 2, 3, 6, and 7 (p < 0.05, p < 0.01, p < 0.01, p < 0.05, and p < 0.05, respectively). These outcomes suggested that risedronate might reduce the periprosthetic bone resorption after cementless THA.